Back to News
Market Impact: 0.2
Canaccord Genuity Initiates Coverage of Seaport Therapeutics with Buy Rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 14, 2026, Canaccord Genuity initiated coverage of Seaport Therapeutics with a Buy recommendation. The stock had closed at $16.08 on October 13, following recent downward movement; the article provides no price target or post-announcement market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
SPTX0.55
More News
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- AI infrastructure stocks tumble. Here's a few reasons for the sell-off
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- A second major Wall Street bank this week is telling clients to cash in tech stocks. Here's why
- Why Dell’s stock was one of the S&P 500’s biggest laggards on Wednesday
- These stocks offer some of the best risk-adjusted upside on Wall Street